Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308334521> ?p ?o ?g. }
- W4308334521 endingPage "5426" @default.
- W4308334521 startingPage "5426" @default.
- W4308334521 abstract "Introduction: Nivolumab (N), pembrolizumab (P), and dabrafenib plus trametinib (D + T) have been registered as adjuvant treatments for resected stage III and IV melanoma since 2018. Electronic health records (EHRs) are a real-world data source that can be used to review treatments in clinical practice. In this study, we applied EHR text-mining software to evaluate the real-world tolerability, safety, and efficacy of adjuvant melanoma treatments. Methods: Adult melanoma patients receiving adjuvant treatment between January 2019 and October 2021 at the Leiden University Medical Center, the Netherlands, were included. CTcue text-mining software (v3.1.0, CTcue B.V., Amsterdam, The Netherlands) was used to construct rule-based queries and perform context analysis for patient inclusion and data collection from structured and unstructured EHR data. Results: In total, 122 patients were included: 54 patients treated with nivolumab, 48 with pembrolizumab, and 20 with D + T. Significantly more patients discontinued treatment due to toxicity on D + T (N: 16%, P: 6%, D + T: 40%), and X2 (6, n = 122) = 14.6 and p = 0.024. Immune checkpoint inhibitors (ICIs) mainly showed immune-related treatment-limiting adverse events (AEs), and chronic thyroid-related AE occurred frequently (hyperthyroidism: N: 15%, P: 13%, hypothyroidism: N: 20%, P: 19%). Treatment-limiting toxicity from D + T was primarily a combination of reversible AEs, including pyrexia and fatigue. The 1-year recurrence-free survival was 70.3% after nivolumab, 72.4% after pembrolizumab, and 83.0% after D + T. Conclusions: Text-mining EHR is a valuable method to collect real-world data to evaluate adjuvant melanoma treatments. ICIs were better tolerated than D + T, in line with RCT results. For BRAF+ patients, physicians must weigh the higher risk of reversible treatment-limiting AEs of D + T against the risk of long-term immune-related AEs." @default.
- W4308334521 created "2022-11-11" @default.
- W4308334521 creator A5006908595 @default.
- W4308334521 creator A5030957904 @default.
- W4308334521 creator A5031300611 @default.
- W4308334521 creator A5034722090 @default.
- W4308334521 creator A5061463742 @default.
- W4308334521 date "2022-11-03" @default.
- W4308334521 modified "2023-09-30" @default.
- W4308334521 title "Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments" @default.
- W4308334521 cites W1756410296 @default.
- W4308334521 cites W2140302476 @default.
- W4308334521 cites W2745416289 @default.
- W4308334521 cites W2752210999 @default.
- W4308334521 cites W2752227448 @default.
- W4308334521 cites W2763494320 @default.
- W4308334521 cites W2783137027 @default.
- W4308334521 cites W2797309423 @default.
- W4308334521 cites W2886457436 @default.
- W4308334521 cites W2946687934 @default.
- W4308334521 cites W2963849817 @default.
- W4308334521 cites W2987654547 @default.
- W4308334521 cites W3005867736 @default.
- W4308334521 cites W3007321116 @default.
- W4308334521 cites W3012770963 @default.
- W4308334521 cites W3027747864 @default.
- W4308334521 cites W3036011106 @default.
- W4308334521 cites W3036449870 @default.
- W4308334521 cites W3081191851 @default.
- W4308334521 cites W3082456432 @default.
- W4308334521 cites W3087697977 @default.
- W4308334521 cites W3128646645 @default.
- W4308334521 cites W3134179448 @default.
- W4308334521 cites W3137633000 @default.
- W4308334521 cites W3137634582 @default.
- W4308334521 cites W3153081776 @default.
- W4308334521 cites W3153228158 @default.
- W4308334521 cites W3164345676 @default.
- W4308334521 cites W3165345393 @default.
- W4308334521 cites W3172878008 @default.
- W4308334521 cites W3179498986 @default.
- W4308334521 cites W3204277760 @default.
- W4308334521 cites W4205373943 @default.
- W4308334521 cites W4206703530 @default.
- W4308334521 cites W4220906555 @default.
- W4308334521 cites W4220951117 @default.
- W4308334521 cites W4281783912 @default.
- W4308334521 cites W4293771029 @default.
- W4308334521 doi "https://doi.org/10.3390/cancers14215426" @default.
- W4308334521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36358844" @default.
- W4308334521 hasPublicationYear "2022" @default.
- W4308334521 type Work @default.
- W4308334521 citedByCount "1" @default.
- W4308334521 countsByYear W43083345212023 @default.
- W4308334521 crossrefType "journal-article" @default.
- W4308334521 hasAuthorship W4308334521A5006908595 @default.
- W4308334521 hasAuthorship W4308334521A5030957904 @default.
- W4308334521 hasAuthorship W4308334521A5031300611 @default.
- W4308334521 hasAuthorship W4308334521A5034722090 @default.
- W4308334521 hasAuthorship W4308334521A5061463742 @default.
- W4308334521 hasBestOaLocation W43083345211 @default.
- W4308334521 hasConcept C121608353 @default.
- W4308334521 hasConcept C126322002 @default.
- W4308334521 hasConcept C143998085 @default.
- W4308334521 hasConcept C151730666 @default.
- W4308334521 hasConcept C184235292 @default.
- W4308334521 hasConcept C197934379 @default.
- W4308334521 hasConcept C2776131300 @default.
- W4308334521 hasConcept C2777658100 @default.
- W4308334521 hasConcept C2777701055 @default.
- W4308334521 hasConcept C2777863537 @default.
- W4308334521 hasConcept C2778375690 @default.
- W4308334521 hasConcept C2778472372 @default.
- W4308334521 hasConcept C2778830669 @default.
- W4308334521 hasConcept C2779343474 @default.
- W4308334521 hasConcept C2780030458 @default.
- W4308334521 hasConcept C2780057760 @default.
- W4308334521 hasConcept C2994587330 @default.
- W4308334521 hasConcept C502942594 @default.
- W4308334521 hasConcept C57074206 @default.
- W4308334521 hasConcept C71924100 @default.
- W4308334521 hasConcept C86803240 @default.
- W4308334521 hasConcept C95444343 @default.
- W4308334521 hasConceptScore W4308334521C121608353 @default.
- W4308334521 hasConceptScore W4308334521C126322002 @default.
- W4308334521 hasConceptScore W4308334521C143998085 @default.
- W4308334521 hasConceptScore W4308334521C151730666 @default.
- W4308334521 hasConceptScore W4308334521C184235292 @default.
- W4308334521 hasConceptScore W4308334521C197934379 @default.
- W4308334521 hasConceptScore W4308334521C2776131300 @default.
- W4308334521 hasConceptScore W4308334521C2777658100 @default.
- W4308334521 hasConceptScore W4308334521C2777701055 @default.
- W4308334521 hasConceptScore W4308334521C2777863537 @default.
- W4308334521 hasConceptScore W4308334521C2778375690 @default.
- W4308334521 hasConceptScore W4308334521C2778472372 @default.
- W4308334521 hasConceptScore W4308334521C2778830669 @default.
- W4308334521 hasConceptScore W4308334521C2779343474 @default.
- W4308334521 hasConceptScore W4308334521C2780030458 @default.